GlassScriptPhysician profile
Kenneth Hardigan
NPI 1437148582
$5,977.18
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,290 · 2020: $1,916 · 2021: $1,157 · 2022: $614.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,375.99 | 2020 | |
| Boston Scientific Corporation | $1,045.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $513.26 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $351.92 | 2019-2022 | |
| Amgen INC. | $342.93 | 2019-2022 | |
| Medtronic, INC. | $336.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $325.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $243.21 | 2019-2022 | |
| Pfizer INC. | $234.89 | 2019-2022 | |
| Abbott Laboratories | $110.51 | 2019 | |
| Merck Sharp & Dohme LLC | $102.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $88.87 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.67 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.46 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $46.86 | 2019 | |
| Amarin Pharma, INC. | $37.27 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $36.69 | 2020-2021 | |
| Bardy Diagnostics, INC. | $28.00 | 2020-2021 | |
| Abiomed | $21.28 | 2019 | |
| Vifor Pharma, INC. | $18.90 | 2021 | |
| Cardiva Medical, INC. | $17.65 | 2021 | |
| Esperion Therapeutics, INC. | $16.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.26 | 2022 | |
| Medtronic Vascular, INC. | $14.84 | 2020 | |
| Atricure, INC. | $12.79 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hardigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.